A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Key facts

Sponsor

AbbVie

Principal Investigator

ABBVIE INC.

AbbVie

Intervention

Adalimumab(drug)

Enrollment

40 enrolled

Eligibility

5-17 years · All sexes

Timeline

2024 – 2028

Study locations (30)

• Arkansas Children's Hospital /ID# 258776, Little Rock, Arkansas, United States
• Childrens National Medical Center /ID# 259284, Washington D.C., District of Columbia, United States
• Joe Dimaggio Children's Hospital Hollywood /ID# 260634, Hollywood, Florida, United States
• Indiana University Health Riley Hospital for Children /ID# 259067, Indianapolis, Indiana, United States
• M Health Fairview University of Minnesota Medical Center - West Bank /ID# 260111, Minneapolis, Minnesota, United States
• Boston Childrens Health Physicians /ID# 258061, Valhalla, New York, United States
• University of North Carolina - Children's Hospital /ID# 259286, Chapel Hill, North Carolina, United States
• MetroHealth Medical Center /ID# 262377, Cleveland, Ohio, United States
• Child Neurology Consultants of Austin /ID# 260562, Austin, Texas, United States
• Monash Health - Monash Medical Centre /ID# 260255, Clayton, Victoria, Australia
• Alberta Children's Hospital /ID# 257880, Calgary, Alberta, Canada
• British Columbia Children and Women's Hospital and Health Centre /ID# 257884, Vancouver, British Columbia, Canada
• Hospital for Sick Children /ID# 257879, Toronto, Ontario, Canada
• CHU Bordeaux - Hopital Pellegrin /ID# 258729, Bordeaux, Nouvelle-Aquitaine, France
• AP-HP - Hopital Bicetre /ID# 258728, Le Kremlin-Bicêtre, Paris, France
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Psoriasis-related juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06751238
  Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
  Novartis Pharmaceuticals
• RECRUITINGPHASE3NCT06869551
  A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
  Bristol-Myers Squibb
• RECRUITINGPHASE3NCT06668181
  An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
  UCB Biopharma SRL
• RECRUITINGPHASE3NCT05767047
  A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
  Amgen
• ACTIVE NOT RECRUITINGPHASE3NCT05083182
  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
  Janssen Research & Development, LLC
• RECRUITINGPHASE3NCT04804553
  Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
  Amgen
• ACTIVE NOT RECRUITINGPHASE3NCT04527380
  A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
  Eli Lilly and Company

See all trials for Psoriasis-related juvenile idiopathic arthritis →